<table border="0" cellpadding="0" cellspacing="0" width="97%" xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<colgroup>
<col width="13.1%"></col>
<col width="19.84%"></col>
<col width="22.86%"></col>
<col width="22.86%"></col>
<col width="21.34%"></col>
</colgroup>
<thead>
<tr>
<th align="justify" colspan="5" stylecode="Lrule Rrule Toprule">
<content stylecode="bold">Table 1: Drugs that may have their plasma concentrations increased by itraconazole </content>
<br/>
</th>
</tr>
<tr>
<th align="justify" stylecode="Lrule Rrule Toprule">
<content stylecode="bold">Drug Class</content>
<br/>
</th>
<th align="justify" stylecode="Lrule Rrule Toprule">
<content stylecode="bold">Contraindicated </content>
<br/>
</th>
<th align="justify" stylecode="Lrule Rrule Toprule">
<content stylecode="bold">Not Recommended </content>
<br/>
</th>
<th align="justify" stylecode="Lrule Rrule Toprule">
<content stylecode="bold">Use with Caution </content>
<br/>
</th>
<th align="justify" stylecode="Lrule Rrule Toprule">
<content stylecode="bold">Comments</content>
<br/>
</th>
</tr>
</thead>
<tbody>
<tr stylecode="Botrule">
<td align="justify" stylecode="Lrule Rrule" valign="top">
<content stylecode="bold"> </content>
<br/>
</td>
<td align="justify" stylecode="Rrule" valign="top">
<content stylecode="italics">Under no circumstances is the drug to be coadministered with itraconazole, and up to two weeks after discontinuation of treatment with itraconazole. </content> <br/>
<content stylecode="bold"> </content>
<br/>
</td>
<td align="justify" stylecode="Rrule" valign="top">
<content stylecode="italics">It is recommended that the use of the drug be avoided during and up to two weeks after discontinuation of treatment with itraconazole, unless the benefits outweigh the potentially increased risks of side effects. If coadministration cannot be avoided, clinical monitoring for signs or symptoms of increased or prolonged effects or side effects of the interacting drug is recommended, and its dosage be reduced or interrupted as deemed necessary. When appropriate, it is recommended that plasma concentrations be measured. The label of the coadministered drug should be consulted for information on dose adjustment and adverse effects. </content>
<content stylecode="bold"> </content>
<br/>
</td>
<td align="justify" stylecode="Rrule" valign="top">
<content stylecode="italics">Careful monitoring is recommended when the drug is coadministered with itraconazole. Upon coadministration, it is recommended that patients be monitored closely for signs or symptoms of increased or prolonged effects or side effects of the interacting drug, and its dosage be reduced as deemed necessary. When appropriate, it is recommended that plasma concentrations be measured. The label of the coadministered drug should be consulted for information on dose adjustment and adverse effects. </content>
<content stylecode="bold"> </content>
<br/>
</td>
<td align="justify" stylecode="Rrule" valign="top">
<content stylecode="bold"> </content>
<br/>
</td>
</tr>
<tr stylecode="Botrule">
<td align="justify" stylecode="Lrule Rrule" valign="top">Alpha Blockers<br/>
</td>
<td align="justify" stylecode="Rrule" valign="top">
<content stylecode="italics"> </content>
<br/>
</td>
<td align="justify" stylecode="Rrule" valign="top">tamsulosin <content stylecode="italics"></content>
<br/>
</td>
<td align="justify" stylecode="Rrule" valign="top">
<content stylecode="italics"> </content>
<br/>
</td>
<td align="justify" stylecode="Rrule" valign="top">
<content stylecode="bold"> </content>
<br/>
</td>
</tr>
<tr stylecode="Botrule">
<td align="justify" stylecode="Lrule Rrule" valign="top">Analgesics <br/> <br/>
</td>
<td align="justify" stylecode="Rrule" valign="top">methadone <br/>
<content stylecode="italics"> </content>
<br/>
</td>
<td align="justify" stylecode="Rrule" valign="top"> <br/>
</td>
<td align="justify" stylecode="Rrule" valign="top">alfentanil, <br/>buprenorphine IV and sublingual, <br/>fentanyl, <br/>oxycodone, <br/>sufentanil <br/>
<content stylecode="italics"> </content>
<br/>
</td>
<td align="justify" stylecode="Rrule" valign="top">
<content stylecode="bold">Methadone: </content>The potential increase in plasma concentrations of methadone when coadministered with itraconazole may increase the risk of serious cardiovascular events including QTc prolongation and <content stylecode="italics">torsade de pointes</content>. <br/>
<content stylecode="bold">Fentanyl: </content>The potential increase in plasma concentrations of fentanyl when coadministered with itraconazole may increase the risk of potentially fatal respiratory depression. <br/>
<content stylecode="bold">Sufentanil: </content>No human pharmacokinetic data of an interaction with itraconazole are available. <content stylecode="italics">In vitro </content>data suggest that sufentanil is metabolized by CYP3A4 and so potentially increased sufentanil plasma concentrations would be expected when coadministered with itraconazole. <content stylecode="bold"></content>
<br/>
</td>
</tr>
<tr stylecode="Botrule">
<td align="justify" stylecode="Lrule Rrule" valign="top">Antiarrhythmics<br/>
</td>
<td align="justify" stylecode="Rrule" valign="top">disopyramide, <br/>dofetilide, <br/>dronedarone, <br/>quinidine <br/>
</td>
<td align="justify" stylecode="Rrule" valign="top"> <br/>
</td>
<td align="justify" stylecode="Rrule" valign="top">digoxin <br/>
</td>
<td align="justify" stylecode="Rrule" valign="top">
<content stylecode="bold">Disopyramide, dofetilide, dronedarone, quinidine: </content>The potential increase in plasma concentrations of these drugs when coadministered with itraconazole may increase the risk of serious cardiovascular events including QTc prolongation. <content stylecode="bold"></content>
<br/>
</td>
</tr>
<tr stylecode="Botrule">
<td align="justify" stylecode="Lrule Rrule" valign="top">Antibacterials<br/> <br/>
</td>
<td align="justify" stylecode="Rrule" valign="top">telithromycin, in subjects with severe renal impairment or severe hepatic impairment <br/>
</td>
<td align="justify" stylecode="Rrule" valign="top">rifabutin <br/>
</td>
<td align="justify" stylecode="Rrule" valign="top">telithromycin <br/>
</td>
<td align="justify" stylecode="Rrule" valign="top">
<content stylecode="bold">Telithromycin: </content>The potential increase in plasma concentrations of telithromycin in subjects with severe renal impairment or severe hepatic impairment, when coadministered with itraconazole may increase the risk of serious cardiovascular events including QT prolongation and torsade de pointes. <br/>
<content stylecode="bold">Rifabutin: </content>See also under ‘Drugs that may decrease itraconazole plasma concentrations’. <content stylecode="bold"></content>
<br/>
</td>
</tr>
<tr stylecode="Botrule">
<td align="justify" stylecode="Lrule Rrule" valign="top">Anticoagulants and Antiplatelet Drugs <br/>
</td>
<td align="justify" stylecode="Rrule" valign="top">ticagrelor <br/>
</td>
<td align="justify" stylecode="Rrule" valign="top">apixaban,<br/>rivaroxaban <br/>
</td>
<td align="justify" stylecode="Rrule" valign="top">coumarins, <br/>cilostazol, <br/>dabigatran <br/>
</td>
<td align="justify" stylecode="Rrule" valign="top">
<content stylecode="bold">Ticagrelor: </content>The potential increase in plasma concentrations of ticagrelor may increase the risk of bleeding.<br/>
<content stylecode="bold">Coumarins: </content>Itraconazole may enhance the anticoagulant effect of coumarin-like drugs, such as warfarin. <content stylecode="bold"></content>
<br/>
</td>
</tr>
<tr stylecode="Botrule">
<td align="justify" stylecode="Lrule Rrule" valign="top">Anticonvulsants <br/>
</td>
<td align="justify" stylecode="Rrule" valign="top"> <br/>
</td>
<td align="justify" stylecode="Rrule" valign="top">carbamazepine <br/>
</td>
<td align="justify" stylecode="Rrule" valign="top"> <br/>
</td>
<td align="justify" stylecode="Rrule" valign="top">
<content stylecode="bold">Carbamazepine: </content>
<content stylecode="italics">In vivo </content>studies have demonstrated an increase in plasma carbamazepine concentrations in subjects concomitantly receiving ketoconazole. Although there are no data regarding the effect of itraconazole on carbamazepine metabolism, because of the similarities between ketoconazole and itraconazole, concomitant administration of itraconazole and carbamazepine may inhibit the metabolism of carbamazepine. See also under ‘Drugs that may decrease itraconazole plasma concentrations’. <content stylecode="bold"></content>
<br/>
</td>
</tr>
<tr stylecode="Botrule">
<td align="justify" stylecode="Lrule Rrule" valign="top">Antidiabetics <br/>
</td>
<td align="justify" stylecode="Rrule" valign="top"> <br/>
</td>
<td align="justify" stylecode="Rrule" valign="top"> <br/>
</td>
<td align="justify" stylecode="Rrule" valign="top">repaglinide, <br/>saxagliptin <br/>
</td>
<td align="justify" stylecode="Rrule" valign="top">
<content stylecode="bold"> </content>
<br/>
</td>
</tr>
<tr stylecode="Botrule">
<td align="justify" stylecode="Lrule Rrule" valign="top">Antihelmintics and Antiprotozoals<br/>
</td>
<td align="justify" stylecode="Rrule" valign="top"> <br/>
</td>
<td align="justify" stylecode="Rrule" valign="top"> <br/>
</td>
<td align="justify" stylecode="Rrule" valign="top">praziquantel <br/>
</td>
<td align="justify" stylecode="Rrule" valign="top">
<content stylecode="bold"> </content>
<br/>
</td>
</tr>
<tr stylecode="Botrule">
<td align="justify" stylecode="Lrule Rrule" valign="top">Antimigraine Drugs <br/> <br/>
</td>
<td align="justify" stylecode="Rrule" valign="top">ergot alkaloids, such as dihydroergotamine, ergometrine (ergonovine), ergotamine, methylergometrine (methylergonovine) <br/> <br/>
</td>
<td align="justify" stylecode="Rrule" valign="top"> <br/>
</td>
<td align="justify" stylecode="Rrule" valign="top">eletriptan <br/>
</td>
<td align="justify" stylecode="Rrule" valign="top">
<content stylecode="bold">Ergot Alkaloids: </content>The potential increase in plasma concentrations of ergot alkaloids when coadministered with itraconazole may increase the risk of ergotism, i.e., a risk for vasospasm potentially leading to cerebral ischemia and/or ischemia of the extremities. <br/>
</td>
</tr>
<tr stylecode="Botrule">
<td align="justify" stylecode="Lrule Rrule" valign="top">Antineoplastics <br/>
</td>
<td align="justify" stylecode="Rrule" valign="top">irinotecan <br/>
</td>
<td align="justify" stylecode="Rrule" valign="top">axitinib, <br/>dabrafenib, <br/>dasatinib, <br/>ibrutinib, <br/>nilotinib, <br/>sunitinib <br/>             trabectedin <br/> <br/>
</td>
<td align="justify" stylecode="Rrule" valign="top">bortezomib, <br/>busulphan, <br/>docetaxel, <br/>erlotinib, <br/>             gefitinib, <br/>imatinib, <br/>ixabepilone, <br/>lapatinib, <br/>ponatinib, <br/>trimetrexate, <br/>vinca alkaloids <br/>
</td>
<td align="justify" stylecode="Rrule" valign="top">
<content stylecode="bold">Irinotecan: </content>The potential increase in plasma concentrations of irinotecan when coadministered with itraconazole may increase the risk of potentially fatal adverse events. <br/>
<content stylecode="bold"> </content>
<br/>
</td>
</tr>
<tr stylecode="Botrule">
<td align="justify" stylecode="Lrule Rrule" valign="top">Antipsychotics, <br/>Anxiolytics and Hypnotics <br/>
</td>
<td align="justify" stylecode="Rrule" valign="top">lurasidone, <br/>oral midazolam, <br/>pimozide, <br/>triazolam<br/>
</td>
<td align="justify" stylecode="Rrule" valign="top"> <br/>
</td>
<td align="justify" stylecode="Rrule" valign="top">alprazolam, <br/>aripiprazole, <br/>buspirone, <br/>diazepam, <br/>haloperidol,<br/>midazolam IV,<br/>perospirone, <br/>quetiapine, <br/>ramelteon, <br/>risperidone <br/>
</td>
<td align="justify" stylecode="Rrule" valign="top">
<content stylecode="bold">Midazolam, triazolam: </content> <br/>Coadministration of itraconazole and oral midazolam, or triazolam may cause several-fold increases in plasma concentrations of these drugs. This may potentiate and prolong hypnotic and sedative effects, especially with repeated dosing or chronic administration of these agents. <br/>
<content stylecode="bold">Pimozide: </content>The potential increase in plasma concentrations of pimozide when coadministered with itraconazole may increase the risk of serious cardiovascular events including QTc prolongation and <content stylecode="italics">torsade de pointes</content>. <content stylecode="bold"></content>
<br/>
</td>
</tr>
<tr stylecode="Botrule">
<td align="justify" stylecode="Lrule Rrule" valign="top">Antivirals <br/> <br/>
</td>
<td align="justify" stylecode="Rrule" valign="top"> <br/>
</td>
<td align="justify" stylecode="Rrule" valign="top">simeprevir <br/> <br/>
</td>
<td align="justify" stylecode="Rrule" valign="top">maraviroc, <br/>indinavir, <br/>ritonavir, <br/>saquinavir <br/>
</td>
<td align="justify" stylecode="Rrule" valign="top">
<content stylecode="bold">Indinavir, ritonavir: </content>See also under ‘Drugs that may increase itraconazole plasma concentrations’. <content stylecode="bold"></content>
<br/>
</td>
</tr>
<tr stylecode="Botrule">
<td align="justify" stylecode="Lrule Rrule" valign="top">Beta Blockers<br/>
</td>
<td align="justify" stylecode="Rrule" valign="top"> <br/>
</td>
<td align="justify" stylecode="Rrule" valign="top"> <br/>
</td>
<td align="justify" stylecode="Rrule" valign="top">nadolol <br/>
</td>
<td align="justify" stylecode="Rrule" valign="top">
<content stylecode="bold"> </content>
<br/>
</td>
</tr>
<tr stylecode="Botrule">
<td align="justify" stylecode="Lrule Rrule" valign="top">Calcium Channel <br/>Blockers<br/>
</td>
<td align="justify" stylecode="Rrule" valign="top">felodipine, <br/>nisoldipine<br/>
</td>
<td align="justify" stylecode="Rrule" valign="top"> <br/>
</td>
<td align="justify" stylecode="Rrule" valign="top">other dihydropyridines, <br/>verapamil <br/> <br/>
</td>
<td align="justify" stylecode="Rrule" valign="top">
<content stylecode="bold">Calcium channel blockers </content>can<content stylecode="bold"></content>have a negative inotropic effect which may be additive to those of itraconazole. The potential increase in plasma concentrations of calcium channel blockers when co-administered with itraconazole may increase the risk of congestive heart failure. <br/>
<content stylecode="bold">Dihydropyridines: </content>Concomitant administration of itraconazole may cause several-fold increases in plasma concentrations of dihydropyridines. Edema has been reported in patients concomitantly receiving itraconazole and dihydropyridine calcium channel blockers. <br/>
</td>
</tr>
<tr stylecode="Botrule">
<td align="justify" stylecode="Lrule Rrule" valign="top">Cardiovascular Drugs, Miscellaneous <br/>
</td>
<td align="justify" stylecode="Rrule" valign="top">Ivabradine<br/>             ranolazine <br/>
</td>
<td align="justify" stylecode="Rrule" valign="top">aliskiren, <br/>sildenafil, for the treatment of pulmonary hypertension <br/>
</td>
<td align="justify" stylecode="Rrule" valign="top">bosentan, <br/>riociguat <br/>
</td>
<td align="justify" stylecode="Rrule" valign="top">
<content stylecode="bold">Ivabradine:</content> The potential increase in plasma concentrations of ivabradine when administered with itraconazole may increase the risk of ivabradine-related adverse events, such as atrial fibrillation, bradycardia, sinus arrest and heart block.<br/>
<content stylecode="bold">Ranolazine: </content>
<br/>The potential increase in plasma concentrations of ranolazine when coadministered with itraconazole may increase the risk of serious cardiovascular events including QTc prolongation. <br/> <br/>
</td>
</tr>
<tr stylecode="Botrule">
<td align="justify" stylecode="Lrule Rrule" valign="top">Diuretics <br/>
</td>
<td align="justify" stylecode="Rrule" valign="top">eplerenone <br/>
</td>
<td align="justify" stylecode="Rrule" valign="top"> <br/>
</td>
<td align="justify" stylecode="Rrule" valign="top"> <br/>
</td>
<td align="justify" stylecode="Rrule" valign="top">
<content stylecode="bold">Eplerenone: </content>The potential increase in plasma concentrations of eplerenone when coadministered with itraconazole may increase the risk of hyperkalemia and hypotension. <br/>
</td>
</tr>
<tr stylecode="Botrule">
<td align="justify" stylecode="Lrule Rrule" valign="top">Gastrointestinal Drugs<br/>
</td>
<td align="justify" stylecode="Rrule" valign="top">cisapride <br/>
</td>
<td align="justify" stylecode="Rrule" valign="top"> <br/>
</td>
<td align="justify" stylecode="Rrule" valign="top">aprepitant <br/> <br/>
</td>
<td align="justify" stylecode="Rrule" valign="top">
<content stylecode="bold">Cisapride: </content>The potential increase in plasma concentrations of cisapride when coadministered with itraconazole may increase the risk of serious cardiovascular events including QTc prolongation. <br/> <br/> <br/> <br/> <br/> <br/>
</td>
</tr>
<tr stylecode="Botrule">
<td align="justify" stylecode="Lrule Rrule" valign="top">Immunosuppres<br/>sants <br/>
</td>
<td align="justify" stylecode="Rrule" valign="top"> <br/>
</td>
<td align="justify" stylecode="Rrule" valign="top">everolimus, <br/>temsirolimus <br/>
</td>
<td align="justify" stylecode="Rrule" valign="top">budesonide, <br/>ciclesonide, <br/>cyclosporine, <br/>dexamethasone,<br/>fluticasone, methylprednisolone,<br/>rapamycin (also known as sirolimus), <br/>tacrolimus<br/>
</td>
<td align="justify" stylecode="Rrule" valign="top">
<content stylecode="bold"> </content>
<br/>
</td>
</tr>
<tr stylecode="Botrule">
<td align="justify" stylecode="Lrule Rrule" valign="top">Lipid Regulating Drugs<br/>
</td>
<td align="justify" stylecode="Rrule" valign="top">lovastatin, <br/>simvastatin<br/>
</td>
<td align="justify" stylecode="Rrule" valign="top"> <br/>
</td>
<td align="justify" stylecode="Rrule" valign="top">atorvastatin <br/>
</td>
<td align="justify" stylecode="Rrule" valign="top">The potential increase in plasma concentrations of atorvastatin, lovastatin, and simvastatin when coadministered with itraconazole may increase the risk of skeletal muscle toxicity, including rhabdomyolysis. <br/>
</td>
</tr>
<tr stylecode="Botrule">
<td align="justify" stylecode="Lrule Rrule" valign="top">Respiratory Drugs  <br/>
</td>
<td align="justify" stylecode="Rrule" valign="top"> <br/>
</td>
<td align="justify" stylecode="Rrule" valign="top">salmeterol  <br/>
</td>
<td align="justify" stylecode="Rrule" valign="top"> <br/>
</td>
<td align="justify" stylecode="Rrule" valign="top"> <br/>
</td>
</tr>
<tr stylecode="Botrule">
<td align="justify" stylecode="Lrule Rrule" valign="top">Urological Drugs <br/>
</td>
<td align="justify" stylecode="Rrule" valign="top">fesoterodine, in subjects with moderate to severe renal impairment, or moderate to severe hepatic impairment, solifenacin, in subjects with severe renal impairment or moderate to severe hepatic impairment <br/>
</td>
<td align="justify" stylecode="Rrule" valign="top">darifenacin, <br/>vardenafil <br/>
</td>
<td align="justify" stylecode="Rrule" valign="top">fesoterodine. <br/>oxybutynin, <br/>sildenafil, for the treatment of erectile dysfunction, <br/>solifenacin, <br/>tadalafil, <br/>tolterodine <br/>
</td>
<td align="justify" stylecode="Rrule" valign="top">
<content stylecode="bold">Fesoterodine: </content>The potential increase in plasma concentrations of the fesoterodine active metabolite may be greater in subjects with moderate to severe renal impairment, or moderate to severe hepatic impairment, which may lead to an increased risk of adverse reactions. <br/>
<content stylecode="bold">Solifenacin: </content>The potential increase in plasma concentrations of solifenacin in subjects with severe renal impairment or moderate to severe hepatic impairment, when coadministered with itraconazole may increase the risk of serious cardiovascular events including QT prolongation. <br/>
</td>
</tr>
<tr>
<td align="justify" stylecode="Lrule Rrule" valign="top">Other <br/>
</td>
<td align="justify" stylecode="Rrule" valign="top">colchicine, in subjects with renal or hepatic impairment <br/>
</td>
<td align="justify" stylecode="Rrule" valign="top">colchicine, conivaptan, tolvaptan <br/>
</td>
<td align="justify" stylecode="Rrule" valign="top">cinacalcet <br/>
</td>
<td align="justify" stylecode="Rrule" valign="top">
<content stylecode="bold">Colchicine: </content>The potential increase in plasma concentrations of colchicine when coadministered with itraconazole may increase the risk of potentially fatal adverse events. <br/>
<content stylecode="bold">Conivaptan and Tolvaptan: </content>A safe and effective dose of either conivaptan or tolvaptan has not been established when coadministered with itraconazole.<content stylecode="bold"></content>
<br/>
</td>
</tr>
</tbody>
</table>